Annual report pursuant to Section 13 and 15(d)

Revenue - Additional Information (Detail)

v3.7.0.1
Revenue - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Aug. 31, 2011
USD ($)
Tranches
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Deferred Revenue Arrangement [Line Items]      
Revenues from product sales   $ 0  
Revenue   5,830,674 $ 2,931,931
Collaboration agreement, milestone payments   $ 1,655,367 $ 2,538,698
Withholding tax   (0.70%) (1.50%)
Collaboration agreement, license upfront payment   $ 2,735,794  
BIO Cluster M4 [Member]      
Deferred Revenue Arrangement [Line Items]      
Funding rate   40.00%  
Grant received   $ 0 $ 8,654
BIO Cluster M4 [Member] | Maximum [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   1,400,000  
European Union [Member] | Seventh Research Framework Program (FP7 Agreement) [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments $ 7,300,000    
Funding rate 64.00%    
Grant received   0.0 400,000
Tranches of payments | Tranches 3    
Collaborative Arrangement [Member]      
Deferred Revenue Arrangement [Line Items]      
Collaboration agreement, milestone payments   0 0
Contractual agreement, potential payments   14,000,000  
Sanofi [Member] | Maximum [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   48,600,000  
Sanofi [Member] | Maximum [Member] | Research Milestones [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   1,800,000  
Sanofi [Member] | Maximum [Member] | Development Milestones [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   27,900,000  
Sanofi [Member] | Maximum [Member] | Commercial Milestones [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   18,900,000  
Sanofi [Member] | Collaborative Arrangement [Member]      
Deferred Revenue Arrangement [Line Items]      
Collaboration agreement, milestone payments   0  
Collaboration agreement, revenue recognized   $ 0 $ 500,000
Daiichi Sankyo Inc [Member]      
Deferred Revenue Arrangement [Line Items]      
Withholding tax   10.00% 10.00%
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member]      
Deferred Revenue Arrangement [Line Items]      
Collaboration agreement, milestone payments   $ 1,700,000 $ 2,000,000
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   85,900,000  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   2,500,000  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   35,200,000  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   47,300,000  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Additional Diagnostic Milestones [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   700,000  
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member]      
Deferred Revenue Arrangement [Line Items]      
Deferred revenue   3,700,000 0
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Upfront Payment Arrangement [Member]      
Deferred Revenue Arrangement [Line Items]      
Collaboration agreement, license upfront payment   6,500,000  
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Research Services [Member]      
Deferred Revenue Arrangement [Line Items]      
Collaboration agreement, revenue recognized   $ 4,100,000 0
Research collaboration agreement, estimated period   20 months  
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Research Services [Member] | Extension Term [Member]      
Deferred Revenue Arrangement [Line Items]      
Research collaboration agreement, estimated period   5 years  
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   $ 399,400,000  
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   277,600,000  
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Sales Milestone Payments [Member]      
Deferred Revenue Arrangement [Line Items]      
Contractual agreement, potential payments   117,700,000  
Collaboration Partner One [Member] | Sales Revenue, Net [Member] | Revenue From Partners [Member]      
Deferred Revenue Arrangement [Line Items]      
Revenue   1,700,000 2,000,000
Collaboration Partner Two [Member] | Sales Revenue, Net [Member] | Revenue From Partners [Member]      
Deferred Revenue Arrangement [Line Items]      
Revenue   $ 4,100,000 500,000
Government Grant [Member] | Sales Revenue, Net [Member] | Revenue From Partners [Member]      
Deferred Revenue Arrangement [Line Items]      
Revenue     $ 400,000